![Nutropin [somatropin (rDNA origin) for injection]: Growing Opportunity](/images/logo-nutropin-growing.png){kind=logo}
Privacy Policy
Genentech, Inc., (“Genentech”) respects the privacy of visitors to its Web sites, and we recognize your need for appropriate protection and management of personally identifiable information you share with us (any information by which you can be identified, including but not limited to, name, address, e-mail address, and telephone number). That is why we have established this Privacy Policy, so that you are informed about how we treat any personally identifiable information that you provide to us in the course of using this Web site. This Privacy Policy will inform you of:
- How you will be informed of updates to this Privacy Policy
- What personally identifiable information of yours we may collect from you through our Web site
- How we may use your personally identifiable information
- Limits on how we would share and disclose your personally identifiable information
- Our policy regarding links to third-party Web sites
- Security of our Web site
- How you can correct and update your personally identifiable information
Please note that the Genentech Web sites are directed towards users who reside in the United States of America. It is not our intent to gather personally identifiable information from individuals residing outside the U.S.
Privacy Policy Updates
Due to the Internet’s rapidly evolving nature, Genentech may need to update this Privacy Policy from time to time. If so, Genentech will post its updated Privacy Policy on our Web site located at Nutropin.com so users are always aware of what personally identifiable information we may collect and how we may use this information. Genentech encourages you to review this Privacy Policy regularly for any changes. Your continued use of this Web site will be subject to the then-current Privacy Policy.
Information Collection and Use
You can generally visit our Web site without revealing any personally identifiable information about yourself. However, to access certain options and services we may ask you to provide certain personally identifiable information and without providing such personally identifiable information, you may be unable to access certain options and services. We (along with our third-party partners engaged to provide marketing and advertising on our behalf) collect personally identifiable information about you only if you voluntarily provide it to us and you have the option not to provide any personally identifiable information to us. The following is personally identifiable information that you may voluntarily provide to us and how we use it:
- Surveys. Information obtained from you on Web surveys, such as contact information (name and shipping address), demographic information (ZIP code, age level), and medical condition. We may use this personally identifiable information to provide you with information and services for which you have expressed an interest or that you may find useful based on your answers in a survey. Additionally, we may refer to your personally identifiable information to better understand your needs and how we can improve our Web site.
- Newsletters. Information obtained from you from your request to subscribe to a newsletter, such as contact information (name and e-mail address). We may use this personally identifiable information to deliver the newsletters that you have elected to receive.
- Registration. Information obtained from you on registration forms used to process your requests for services and information, such as contact information (name, address, e-mail address), password, username or code, age, date of birth, gender, ethnicity, and medical condition. This registration information may also be gathered if you register for certain services via fax or mail. We may use this information to send you a welcoming e-mail to verify your username and password, Web site updates, special offers, notices regarding relevant medical conditions and treatment, or other information responsive to the data that you provide to us. Additionally, we may refer to your personally identifiable information to better understand your needs and how we can improve our Web site.
- E-Mail Content to a Friend. Information obtained from you regarding friend or family name and e-mail address, if you elect to use our referral service for sending some of our Web site content to friends and family. We may use this personally identifiable information to automatically send the friend or family member a one-time e-mail inviting them to visit the Web site. We may store this information for the sole purpose of sending this one-time e-mail.
Genentech is the owner of all information collected on this Web site.
Minors
You must be 18 years of age or older to submit registration or survey information. If you are under the age of 18 and wish to register to obtain further information or be included in a survey, then your parent or legal guardian must register to obtain the information or to participate in the survey.
Privacy Statement for Children
Our Web sites are not intended or designed to attract children under the age of 13. Moreover, we do not knowingly collect any personally identifiable information from anyone under the age of 18 without the consent of the parent or guardian. Should you believe that a minor for which you are a parent or guardian has registered, please contact us at privacy.office@gene.com and we will make reasonable efforts to remove all personally identifiable information related to the minor.
Cookies and GIF Files
Some of our Web sites may use cookie technology to identify users who have previously visited so the user is recognized upon return, thereby saving them time while on our Web site. A cookie is a piece of data stored on the user’s hard drive containing information about the user. Usage of a cookie is in no way linked to any personally identifiable information while on our Web site. Once the user closes their browser, the cookie simply terminates. If a user rejects the cookie, they may still use our Web site. A cookie may be placed by us, or by vendors or service agencies who work with us or with our partners.
This Web site may use pixels, or transparent GIF files, to help manage online advertising. These GIF files are provided by our ad management partners. These files enable these partners to recognize a unique file on your Web browser, which in turn enables us to learn which advertisements bring users to our Web site. The information contained in GIF files that we collect and share with our ad management partners is anonymous and is not personally identifiable.
Log Files and Aggregate Information
We may track the total number of visitors to our Web site, the number of visitors to each page of our Web site, IP addresses, and the domain names of our users’ Internet Service Providers, and we may analyze these data for trends and statistics in the aggregate, but such information will be in aggregate form only and it will not contain personally identifiable data. Such aggregate information is not linked to any personally identifiable information that can identify any individual person.
We may use such aggregate information to analyze trends, administer the Web site, track user’s movement, and gather broad demographic information for aggregate use. We may share this aggregate information with our corporate partners and contracted vendors to assist us in operating the Web site and to enable them to better understand Genentech’s business.
Sharing and Disclosure
We may provide your personally identifiable information that we collect and the data generated by cookies to a parent, subsidiary, or affiliate entity within the Genentech corporate family, partner entities, and the vendors and service agencies that we may engage to assist us. For example, we may provide your personally identifiable information to an organization in order to complete a service (e.g., send out newsletter e-mails you have requested), to assist us in reviewing the data or to provide marketing or advertising on our behalf. Any organization to which we provide such personally identifiable information is also required to keep your personally identifiable information confidential in accordance with this Privacy Policy. We will also disclose your personally identifiable information if we reasonably believe we are required to do so by law, regulation, or other government authority (such as reporting safety information to the Food and Drug Administration). We will not sell your personally identifiable information to any other company or organization except we may transfer your personally identifiable information to a successor entity upon a merger, consolidation, or other corporate reorganization in which Genentech participates or to a purchaser of all or substantially all of Genentech’s assets. Such successor entity shall be bound by the terms and conditions of this Privacy Policy.
Links to Third-Party Sites
Some of our Web sites may contain links to other Web sites on the Internet that are not under the control of or maintained by Genentech. Such links do not constitute an endorsement by Genentech of those other Web sites, the content displayed therein, or the persons or entities associated therewith. You acknowledge that Genentech is providing these links to you only as a convenience, and you agree that Genentech is not responsible for the content of such Web sites. Your use of these other linked Web sites is subject to the respective terms of use and privacy policies located on the linked Web sites.
Security
Genentech and its third-party providers may employ procedural and technological security measures, consistent with industry practice. Such measures are reasonably designed to protect your personally identifiable information from loss, unauthorized access, disclosure, alteration or destruction. Genentech may use encryption, password protection, secure socket layers, internal restrictions, and other security measures to help prevent unauthorized access to your personally identifiable information.
Correction/Updating Personally Identifiable Information
Genentech provides you with the ability to review and correct any of the personally identifiable information that you have provided to us. If you wish to correct any information provided to us, you may update your contact information directly by accessing your account or registration. You may also “opt-out” of receiving e-mails and other communications from us by using the unsubscribe feature included in the e-mails we send.
Privacy Policy Last updated: June 9, 2005.
INDICATIONS
Pediatric Patients
Nutropin AQ® [somatropin (rDNA origin) injection] and Nutropin [somatropin (rDNA origin) for injection] are indicated for the long-term treatment of growth failure due to a lack of adequate endogenous GH secretion.
Nutropin AQ and Nutropin are also indicated for the treatment of growth failure associated with chronic renal insufficiency up to the time of renal transplantation. Nutropin AQ and Nutropin therapy should be used in conjunction with optimal management of chronic renal insufficiency.
Nutropin AQ and Nutropin are also indicated for the long-term treatment of short stature associated with Turner syndrome.
Nutropin AQ and Nutropin are also indicated for the long-term treatment of idiopathic short stature, also called non-growth hormone deficient short stature, defined by height SDS ≤-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.
Adult Patients
Nutropin AQ and Nutropin are indicated for replacement of endogenous GH in adults with GH deficiency who meet either of the following two criteria:
- Adult-Onset: Patients who have GH deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
- Childhood-Onset: Patients who were GH deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.
In general, confirmation of the diagnosis of adult GH deficiency in both groups usually requires an appropriate GH stimulation test. However, confirmatory GH stimulation testing may not be required in patients with congenital/genetic GH deficiency or multiple pituitary hormone deficiencies due to organic disease.
IMPORTANT SAFETY INFORMATION
Contraindications
GROWTH HORMONE (GH) SHOULD NOT BE USED IN PATIENTS WITH:
- Closed epiphyses for pediatric growth promotion
- Active proliferative or severe non-proliferative diabetic retinopathy
- Active malignancy
- Acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma, or those with acute respiratory failure
- Prader-Willi syndrome who are severely obese or have severe respiratory impairment. Nutropin AQ and Nutropin are not indicated in patients with Prader-Willi syndrome who do not also have a diagnosis of GH deficiency
- Known sensitivity to benzyl alcohol when using Nutropin reconstituted with Bacteriostatic Water for Injection, USP (benzyl alcohol preserved). For use in newborns, see WARNINGS in full Prescribing Information
Additional Safety Information
- Nutropin AQ and Nutropin should be prescribed by physicians experienced in the diagnosis and management of patients with pediatric or adult GH deficiency, Turner syndrome (TS), or chronic renal insufficiency (CRI).
- Patients should be monitored for signs of glucose intolerance. Patients taking antihyperglycemic agents may require dose adjustment when GH therapy is instituted.
- Patients with preexisting tumors or growth hormone deficiency secondary to an intracranial lesion should be examined routinely for progression or recurrence of the underlying disease process.
- Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in a small number of patients treated with GH products.
- In patients with hypopituitarism (multiple hormone deficiencies), standard hormonal replacement therapy should be monitored closely when GH therapy is administered.
- Periodic thyroid function tests and thyroid replacement therapy should be initiated or appropriately adjusted when indicated.
- Injection site discomfort has been reported.
- Rotate injection site to avoid tissue atrophy that may result from subcutaneous administration of GH at the same site over a long period of time.
- As with any protein, local or systemic allergic reactions may occur.
Pediatric Patients
- Slipped capital femoral epiphysis may occur more frequently in patients with endocrine disorders or in patients undergoing rapid growth.
- Children with growth failure secondary to CRI should be examined periodically for evidence of progression of renal osteodystrophy.
- Progression of scoliosis can occur in patients who experience rapid growth. Patients with a history of scoliosis who are treated with GH should be monitored for progression of scoliosis.
Adult Patients
- GH therapy may cause fluid retention.
- Carpal tunnel syndrome, arthralgia, and other joint disorders have been reported in GH-treated patients.
Drug Interactions
- Patients on GH therapy, with previously undiagnosed central (secondary) hypoadrenalism, may require glucocorticoid replacement therapy. Patients already on glucocorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses.
- Glucocorticoid replacement therapy should be carefully adjusted in children with concomitant GH and glucocorticoid deficiency to avoid both hypoadrenalism and an inhibitory effect on growth.
- Careful monitoring is advisable when GH is given in any combination with agents metabolized by CP450 liver enzymes.
- In women on oral estrogen replacement, a larger dose of somatropin may be required to achieve the defined treatment goal.
Please see full Prescribing Information for additional Important Safety Information.
The content available from this website is for informational purposes only. Individual results may vary. You may report side effects to the FDA at 1-800-FDA-1088 or to Genentech Drug Safety/Adverse Events at 1-888-835-2555.
Nutropin and Nutropin AQ are registered trademarks; and NuSpin, growingopportunity, and Nutropin GPS are trademarks of Genentech Inc.
